Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969197 | 0.97 | TSHR (0.33) | TSHRMEN1GAAKMT2A | |
| SCHEMBL23111823 | 0.95 | TSHR (0.35) | TSHRMEN1GAAKMT2A | |
| SCHEMBL4858440 | 0.94 | LMNA (0.31) | — | |
| SCHEMBL23355067 | 0.91 | LMNA (0.33) | — | |
| SCHEMBL21333948 | 0.91 | PRKCA (0.33) | — | |
| SCHEMBL22104501 | 0.85 | PRKCA (0.38) | MEN1KMT2A | |
| SCHEMBL3780732 | 0.84 | TSHR (0.36) | TSHRSLC22A6 | |
| SCHEMBL28854141 | 0.81 | ALDH1A1 (0.35) | — | |
| SCHEMBL29407564 | 0.81 | — | — | |
| SCHEMBL22064509 | 0.81 | FAAH (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4009857-B1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORP (US) | 2025-08-20 | — | — | EP | claimed |
| US-20250041485-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORPORATION | 2025-02-06 | — | — | US | claimed |
| US-12151048-B2 | Bioerodible cross-linked hydrogel implants and related methods of use | DOSE MEDICAL CORPORATION (US) | 2024-11-26 | — | — | US | claimed |
| US-20220323650-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORPORATION | 2022-10-13 | — | — | US | claimed |
| US-11383006-B2 | Bioerodible cross-linked hydrogel implants and related methods of use | DOSE MEDICAL CORPORATION (US) | 2022-07-12 | — | — | US | claimed |
| EP-4009857-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE Medical Corporation (US) | 2022-06-15 | — | — | EP | claimed |
| EP-3976124-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE Medical Corporation (US) | 2022-04-06 | — | — | EP | claimed |
| US-20210038769-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORPORATION | 2021-02-11 | — | — | US | claimed |
| WO-2021026214-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORPORATION (US) | 2021-02-11 | — | — | WO | claimed |
| US-20200375891-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORP (US) | 2020-12-03 | — | — | US | claimed |
| WO-2020243602-A1 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | DOSE MEDICAL CORPORATION (US) | 2020-12-03 | — | — | WO | claimed |
| US-20250041475-A1 | MEDICAL TISSUE ADHESIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING BIOSIS HEALING BIOLOGICAL TECHNOLOGY CO., LTD (CN) | 2025-02-06 | — | — | US | disclosed |
| EP-4450095-A1 | MEDICAL TISSUE ADHESIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Biosis Healing Biological Technology Co., Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| EP-3793622-A1 | EMBOLIC COMPOSITIONS AND METHODS | Incept, LLC (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2017015616-A1 | OCULAR PROTEIN DELIVERY | ENVISIA THERAPEUTICS, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2004050897-A2 | METHODS FOR PREPARING ANTIGEN MASKED RED BLOOD CELLS HAVING REDUCED HEMOLYSIS BY SERA | CERUS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050848-A2 | METHODS FOR ANTIGEN MASKING OF RED BLOOD CELLS RESULTING IN REDUCED HEMOLYSIS | CERUS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004049914-A2 | METHODS FOR REACTING AN ANTIGEN MASKING COMPOUND WITH RED BLOOD CELLS WITH HIGH EFFICIENCY | CERUS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-1996021036-A2 | NUCLEIC ACID CONDENSING AGENTS WITH REDUCED IMMUNOGENICITY | CHIRON VIAGENE, INC. (US) | 1996-07-11 | — | — | WO | disclosed |